Roxane Furosemide Tablets: Unusually Thick Tablets Recalled
Roxane Laboratories recalls 20mg Furosemide tablets due to unusually thick tablets reported in complaints. This may affect prescription medication safety.
Lower-risk recall
Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint.
Contact the company
What happened, in plain English
Roxane Laboratories is recalling 20mg Furosemide tablets that were reported to have unusually thick tablets. This could potentially affect the medication's performance or safety when taken. Read more at govinfonow.com/recall/42110-roxane-furosemide-tablets-unusually-thick-tablets-recalled.
Source Summary by GovInfoNow · govinfonow.com/recall/42110-roxane-furosemide-tablets-unusually-thick-tablets-recalled · Updated October 8, 2026 · FDA enforcement record: FDA #D-0437-2017
Cite this page
“Roxane Furosemide Tablets: Unusually Thick Tablets Recalled.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/42110-roxane-furosemide-tablets-unusually-thick-tablets-recalled. Based on FDA recall #D-0437-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0437-2017%22&limit=1).
Why it’s dangerous
The tablets were reported to be unusually thick, which could potentially affect how the medication dissolves in the body or its effectiveness. However, the hazard is not described as causing serious injury or death.
Who’s affected
Prescription holders of Furosemide Tablets USP 20mg 1000-count bottles from Roxane Laboratories. People taking this medication for conditions like heart failure or edema may be affected.
How to tell if you have this one
Look for Furosemide Tablets USP 20mg 1000-count bottles with NDC 0054-4297-31. The lot number 660833A was produced and expires August 31, 2018.
- Brand
Roxane Laboratories- Category
Drug
What to do — step by step
Check Medication Details
Verify the product name, strength, and lot number on your prescription bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 12 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0437-2017 (December 22, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0437-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.